NCT07096843 - A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Primary Membranous Nephropathy

Interventions

DRUG

budoprutug

Single IV dose of study product on Day 1, Day 15, Day 169 and Day 183

Trial Locations (13)

12065

RECRUITING

Climb Bio Investigative Site #101, Clifton Park

19104

NOT_YET_RECRUITING

Climb Bio Investigative Site #102, Philadelphia

30342

RECRUITING

Climb Bio Investigative Site #108, Atlanta

32086

RECRUITING

Climb Bio Investigative Site #105, Orlando

33027

NOT_YET_RECRUITING

Climb Bio Investigative Site #804, Rivne

46002

NOT_YET_RECRUITING

Climb Bio Investigative Site #802, Ternopil

46268

NOT_YET_RECRUITING

Climb Bio Investigative Site #106, Indianapolis

63376

NOT_YET_RECRUITING

Climb Bio Investigative Site #109, City of Saint Peters

75092

RECRUITING

Climb Bio Investigative Site #104, Sherman

76008

NOT_YET_RECRUITING

Climb Bio Investigative Site #803, Ivano-Frankivsk

80220

RECRUITING

Climb Bio Investigative Site #110, Denver

02125

NOT_YET_RECRUITING

Climb Bio Investigative Site# 801, Kyiv

03151

NOT_YET_RECRUITING

Climb Bio Investigative Site #805, Kyiv